- Insulin degludec/liraglutide (IDegLira) plus a sodium-glucose cotransporter 2 inhibitor (SGLT2i) is more effective than insulin glargine (IGlar U100) plus SGLT2i for glycemic control, body weight, and total daily insulin dose.
Why this matters
- There is a need for treatment intensification when treating progressive type 2 diabetes mellitus (T2DM).
- 26-week, phase 3b, open-label, randomized trial.
- 420 patients with T2D were randomly assigned 1:1 to either IDegLira plus SGLT2i or IGlar U100.
- HbA1c, body weight, insulin dose, and number of hypoglycemia (HG) episodes were analyzed.
- Funded by: Novo Nordisk A/S.
- Significant reduction of HbA1c from baseline to week 26 for IDegLira compared with IGlar U100 (8.2%-6.3% vs 8.4%-6.7%; P<.0001>
- IDegLira group observed an unchanged mean body weight, while a 2.0 kg mean weight gain was seen in the IGlar U100 group (P<.0002>
- 58% lower HG rate with IDegLira vs IGlarU100 (P=.0035).
- Total daily insulin dose was 36U for IDegLira vs 54U for IGlarU100 (P<.0001>
- No cost analysis of IDegLira.